SK Pharmteco affiliate Ampac Fine Chemicals (AFC) has added a complex molecule chemistry and engineering centre at its main site in Rancho Cordova, California. “This expands upon our core technologies such as energetic chemistry, high potency, chromatography and continuous processing”, said Dr John Jacobsen, executive director of R&D.
A new CPHI report highlights a significant shift in the pharma outsourcing market
Siegfried has held a groundbreaking ceremony for the largest construction project in its history. The Swiss CDMO will be investing up to CHF 100 million on a large-scale production facility at Minden, Germany. This will have up to 100 m3 of additional reactor capacity for API production when it is commissioned in 2024.
Edgewater Capital Partners, a lower middle-market private equity firm which has made previous investments in life Sciences and pharma services, has acquired GL Chemtec of Oakville, Ontario, a CRO which offers chemistry R&D and scale-up services to support API development, plus advanced materials for drug delivery, medical devices and other life science applications. No financial details were disclosed.
Ube has agreed to acquire all of the shares of the CDMO and API manufacturer API Corporation (APIC) from its Japanese compatriot Mitsubishi Chemical. Terms were not disclosed.
APIC offers such CDMO services for small molecule drugs as synthetic route design, pilot manufacturing, investigational medical manufacturing and commercial production based on capabilities in both organic synthesis and biotechnology it has cultivated over many years. It also makes APIs and intermediates.
Following on from a decision last year to evaluate options to boost value, the board of Labcorp has authorised a spin-off of its clinical development business to shareholders through a tax-free transaction. This should be completed in 2H 2023.
LabCorp is expected to continue being publicly traded on the New York Stock Exchange and the clinical development business should also be publicly listed. This will lead to the creation of two independent companies with “distinct strategic priorities, customer needs and value creation”, the company said:
WuXi AppTec has announced a plan to build a new R&D and manufacturing site in Singapore at a cost of up to $1.4 billion. It will be created in stages over the next ten years, depending on the company’s business needs.
The company added that the site will serve “a critical role in its global network across Asia, Europe and North America”. It ill include “laboratories and facilities that provide a broad portfolio of R&D and manufacturing services” for the pharmaceutical industry.
